The Food and Drug Administration (FDA) has approved Enzeevu ™ (aflibercept-abzv), a biosimilar to Eylea ® (aflibercept). Enzeevu is a vascular endothelial growth factor inhibitor indicated for ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

The US Food and Drug Administration (FDA) has approved Sandoz’s Enzeevu (aflibercept-abzv), the drugmaker’s biosimilar for wet age-related macular degeneration (AMD). Available as a 2mg vial ...

The Mylight study confirmed equivalent efficacy, as well as comparable safety and immunogenicity for Sandoz biosimilar aflibercept and reference medicine Eylea (aflibercept) as per Eylea approved ...

No-moat Sandoz received Food and Drug Administration approval for Enzeevu, biosimilar to Eylea (aflibercept). Enzeevu is approved to treat neovascular age-related macular degeneration. We think ...

Another FDA-approved biosimilar of Eylea is Ahzantive (aflibercept-mrbb). Last month, the FDA also approved Sandoz biosimilar, Enzeevu, for the same. Regeneron is involved in various lawsuits for ...

Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal ...

Despite legal setbacks from Amgen's Eylea biosimilar, the legal battle continues, and REGN's patents protect EYLEA HD until at least 2037. Moreover, Dupixent and Libtayo remain strong growth ...

The other three — Tofidence™ and Tyenne® for Actemra® (tocilizumab) and Pavblu™ for Eylea® (aflibercept) — were the first commercially available biosimilars for their respective ...

Eylea is a biologic drug, which means it’s made from parts of living organisms. It doesn’t come in a biosimilar form. Biosimilars are like generic drugs. Unlike generics, which are made for ...